title: Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication.
abstract: Pergolide has proven significantly superior to L-dopa plus peripheral decarboxylase inhibitor in short-term therapy of RLS/NMS. We now first present long-term follow-up sleep data showing its lastingly good effects after averagely 517 treatment days.
authors.affiliation: Department of Psychiatry, University of Göttingen, Federal Republic of Germany.
authors.forename: J
authors.initials: J
authors.lastname: Staedt
authors.forename: H
authors.initials: H
authors.lastname: Hünerjäger
authors.forename: E
authors.initials: E
authors.lastname: Rüther
authors.forename: G
authors.initials: G
authors.lastname: Stoppe
mesh_terms: D018726:Anti-Dyskinesia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004569:Electroencephalography / Q000187:drug effects; D004576:Electromyography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use*; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D018726:Anti-Dyskinesia Agents; D010479:Pergolide